You are here

  • Home
  • Archive
  • Volume 104, Issue 13
  • Does the purported mortality benefit of beta-blocker therapy in heart failure with a preserved ejection fraction apply to patients without prior myocardial infarction?

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Does the purported mortality benefit of beta-blocker therapy in heart failure with a preserved ejection fraction apply to patients without prior myocardial infarction?
  1. Nilay Kumar
  1. Correspondence to Dr Nilay Kumar, Department of Medicine, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI 53706, USA; nkumar39{at}wisc.edu

http://dx.doi.org/10.1136/heartjnl-2018-313079

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor We read with interest the study by Zheng et al in which the authors conducted a meta-analysis of randomised controlled trials to evaluate the effect of different drug classes in heart failure with a preserved ejection fraction (HFpEF). Primary outcome was all-cause mortality and secondary outcome was cardiovascular mortality among other secondary outcomes. The authors found that beta-blocker therapy led to significant reductions in all-cause …

    View Full Text

    Footnotes

    • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles